Compare BBNX & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBNX | TOI |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | 423 | 641 |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 565.9M |
| IPO Year | N/A | N/A |
| Metric | BBNX | TOI |
|---|---|---|
| Price | $15.85 | $4.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $23.80 | $6.67 |
| AVG Volume (30 Days) | 994.2K | ★ 2.2M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.90 | $30.15 |
| Revenue Next Year | $34.63 | $25.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $2.32 |
| 52 Week High | $32.71 | $6.67 |
| Indicator | BBNX | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 43.73 |
| Support Level | $9.34 | $4.90 |
| Resistance Level | $32.52 | $5.63 |
| Average True Range (ATR) | 1.17 | 0.42 |
| MACD | -0.25 | -0.12 |
| Stochastic Oscillator | 18.16 | 2.11 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.